Efficacy
PD
REGRESSION, DISEASE PROGRESSION, DISEASE
The primary endpoint was PFS6 and only one patient was in progression‐free status at 6 months (PFS6 = 5.6% [The median progression‐free survival was 1.7 months (range: 0.9–7.2 months) and median overall survival was 5.7 months (range: 2–22.0 months). Objective response rate was 5.6% (1 PR) and disease‐control rate was 22.2% (1 PR and 3 SD) by RANO criteria (Figure Radiographic response of existing lesion(s) following GC1118 treatment. We measured the two diameters of target lesion(s) on T1 post‐contrast images and computed products of perpendicular diameters. We compared the sum of products with baseline to evaluate the radiographic response and presented the best response in each case. Overall response was assessed by RANO criteria and presented with different colors (black‐PD; gray‐SD; white‐PR). *indicates development of new lesion including leptomeningeal seeding. All patients marked with * showed a decrease or stable state of target lesion(s); however, they were assessed as having disease progression owing to developing new lesion(s) remote from the original target lesion(s). PD, progression of disease; PR, partial response; SD, stable disease.A single patient exhibited a notable response to GC1118; patient SMC‐0002 showed regression of a contrast‐enhancing lesion following GC1118 treatment (Figure 